Papers
6
Total Citations
116
H-Index
3
About
Roshni Rao is a leading radiation oncologist whose research centers on refining stereotactic body radiation therapy (SBRT) for early-stage breast cancer, with a particular focus on partial-breast irradiation (PBI). Her major contributions stem from pioneering phase 1 dose-escalation trials that systematically evaluate the safety, tolerability, and cosmetic outcomes of delivering radiation in fewer, higher-dose fractions—both 5-fraction and single-fraction regimens—after lumpectomy. Rao’s 2017 paper on 5-fraction SBRT for partial-breast irradiation, with 66 citations, established foundational evidence for this approach, while her 2021 multi-institutional single-fraction trial (23 citations) advanced the field by testing the feasibility of ultra-hypofractionation. She has also rigorously assessed cosmetic results, ensuring that treatment intensification does not compromise patient-reported outcomes. Her work is notable for its methodical dose escalation design, which has helped define maximum tolerated doses and set the stage for broader adoption of shorter, more convenient breast radiotherapy. With a cumulative citation impact exceeding 115 across her most-cited works, Rao’s research directly informs clinical practice, offering patients with early-stage breast cancer a less burdensome yet equally effective treatment alternative.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6